JP2006514636A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514636A5
JP2006514636A5 JP2004557434A JP2004557434A JP2006514636A5 JP 2006514636 A5 JP2006514636 A5 JP 2006514636A5 JP 2004557434 A JP2004557434 A JP 2004557434A JP 2004557434 A JP2004557434 A JP 2004557434A JP 2006514636 A5 JP2006514636 A5 JP 2006514636A5
Authority
JP
Japan
Prior art keywords
composition
wta
infection
antibody
staphylococcal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004557434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514636A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/038132 external-priority patent/WO2004050846A2/en
Publication of JP2006514636A publication Critical patent/JP2006514636A/ja
Publication of JP2006514636A5 publication Critical patent/JP2006514636A5/ja
Pending legal-status Critical Current

Links

JP2004557434A 2002-12-02 2003-12-01 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸 Pending JP2006514636A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43022502P 2002-12-02 2002-12-02
PCT/US2003/038132 WO2004050846A2 (en) 2002-12-02 2003-12-01 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines

Publications (2)

Publication Number Publication Date
JP2006514636A JP2006514636A (ja) 2006-05-11
JP2006514636A5 true JP2006514636A5 (cg-RX-API-DMAC7.html) 2007-06-07

Family

ID=32469426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004557434A Pending JP2006514636A (ja) 2002-12-02 2003-12-01 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸

Country Status (6)

Country Link
US (1) US20040247605A1 (cg-RX-API-DMAC7.html)
EP (1) EP1567868A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006514636A (cg-RX-API-DMAC7.html)
AU (2) AU2003298770A1 (cg-RX-API-DMAC7.html)
CA (1) CA2507711A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004050846A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
WO2007024852A2 (en) * 2005-08-22 2007-03-01 Biosynexus Incorporated Methods for testing vaccine candidates against bacterial infection in rodents
AU2006303998A1 (en) * 2005-10-11 2007-04-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Targeted biocides
AU2008292897B2 (en) * 2007-08-31 2015-01-22 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
US8598342B2 (en) 2008-06-12 2013-12-03 President And Fellows Of Harvard College Methods and compounds for antimicrobial intervention
KR20110124060A (ko) * 2010-05-10 2011-11-16 부산대학교 산학협력단 Wta를 유효성분으로 함유하는 백신 조성물
EP2780351B1 (en) 2011-11-18 2019-12-18 National Research Council of Canada (NRC) Clostridium difficile lipoteichoic acid and uses thereof
CN103383354B (zh) * 2012-05-03 2016-11-09 北京博迈世纪生物技术有限公司 一种检测肠毒素sea的磁微粒化学发光试剂盒的检测方法
EP2848257A4 (en) * 2012-05-07 2015-12-02 Mogam Biotechnology Inst VACCINE COMPOSITION FOR PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS
AR096388A1 (es) * 2013-05-31 2015-12-30 Genentech Inc Anticuerpos anti-ácido teicoico de pared y sus conjugados
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
BR112015029754A2 (pt) * 2013-05-31 2017-09-26 Genentech Inc anticorpos anti-teicoico da parede e conjugados
EP3381939A1 (en) * 2013-05-31 2018-10-03 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
CN106413737A (zh) * 2014-05-29 2017-02-15 株式会社绿十字 用于预防或治疗金黄色葡萄球菌感染的组合物
BR112017011325A2 (pt) * 2014-12-03 2020-07-21 Genentech, Inc. ?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?
WO2017010845A1 (ko) * 2015-07-15 2017-01-19 재단법인 목암생명과학연구소 포도상구균 감염 질환의 예방 또는 치료용 조성물
JP2019519509A (ja) * 2016-05-18 2019-07-11 ゲンマブ ビー.ブイ. 感染性疾患の治療における抗体およびその使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250262A (en) * 1979-12-14 1981-02-10 Forsyth Dental Infirmary For Children Method of preparing a purified glucosyltransferase
US5139933A (en) * 1989-09-26 1992-08-18 Vicam, L.P. Assay method for detecting listeria
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5290707A (en) * 1991-11-25 1994-03-01 The United States Of America As Represented By The Secretary Of The Army Method for detection of microorganisms
US5367058A (en) * 1993-08-25 1994-11-22 Becton, Dickinson And Company Modified antibodies with increased affinity
EP0732936B1 (de) * 1993-12-09 2000-03-29 Heinrich Exner Adjuvans für antigene, verfahren zur herstellung und verwendung
US6350597B1 (en) * 1994-01-13 2002-02-26 E. I. Du Pont De Nemours & Company Riboflavin synthase genes and enzymes and methods of use
US6203997B1 (en) * 1994-06-08 2001-03-20 Sepsis, Inc. Quantitation of analytes in whole blood
ES2178699T3 (es) * 1995-01-30 2003-01-01 Lunamed Ag Preparaciones antitumorales que contienen un acido lipoteicoico procedente de streptococcus.
EP0861321B1 (en) * 1995-10-13 2006-05-31 President And Fellows Of Harvard College Phosphopantetheinyl transferases and uses thereof
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US5889171A (en) * 1997-07-18 1999-03-30 Smithkline Beecham Corporation TarF
ATE316794T1 (de) * 1997-07-23 2006-02-15 Ambi Inc Pharmazeutische zusammensetzungen enthaltend lysostaphin allein oder in kombination mit einem antibiotikum zur behandlung von staphylokokkeninfektionen
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) * 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US6585973B1 (en) * 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
KR100790653B1 (ko) * 1998-12-22 2007-12-31 마이크로싸이언스 리미티드 유전자와 단백질들, 및 그들의 사용
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
CA2369762A1 (en) * 1999-04-16 2000-10-26 Peter P. Lee A method for improving the half-life of soluble viral-specific ligands on mucosal membranes
US6974700B2 (en) * 1999-06-14 2005-12-13 Martin Levine Kit for use in predicting refractory periodontal disease
WO2002045742A2 (en) * 2000-09-12 2002-06-13 U.S. Army Medical Research And Materiel Command Lipoteichoic acid immunogenic compositions and methods of making and using thereof
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
US6720160B2 (en) * 2001-10-11 2004-04-13 Helica Biosystems, Inc. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals
US7169903B2 (en) * 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
EP1474432A1 (en) * 2002-02-04 2004-11-10 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
FR2842210B1 (fr) * 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
US20040109853A1 (en) * 2002-09-09 2004-06-10 Reactive Surfaces, Ltd. Biological active coating components, coatings, and coated surfaces
EP2392582A3 (en) * 2003-04-25 2012-03-07 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses therefore
US7422755B2 (en) * 2004-01-15 2008-09-09 The United States Of America As Represented By The Department Of Health And Human Services Antimultiorganism glycoconjugate vaccine
KR100596443B1 (ko) * 2004-04-27 2006-07-05 주식회사 하이닉스반도체 다수 뱅크 구조 디램을 위한 리프레시 제어회로 및 그 방법
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
US20060269998A1 (en) * 2005-04-15 2006-11-30 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
US7521535B2 (en) * 2006-09-20 2009-04-21 The Board Of Regents For Oklahoma State University Anti-microbial defensin-related peptides and methods of use

Similar Documents

Publication Publication Date Title
JP2006514636A5 (cg-RX-API-DMAC7.html)
JP2021063090A5 (cg-RX-API-DMAC7.html)
JP2017512193A5 (cg-RX-API-DMAC7.html)
JP2019518742A5 (cg-RX-API-DMAC7.html)
JP2007511593A5 (cg-RX-API-DMAC7.html)
JP2016507470A5 (cg-RX-API-DMAC7.html)
JP2015534579A5 (cg-RX-API-DMAC7.html)
CA2544920A1 (en) Method for the treatment of multiple sclerosis by inhibiting il-17 activity
JP2019031565A5 (cg-RX-API-DMAC7.html)
JP2013515079A5 (cg-RX-API-DMAC7.html)
JP2017514461A5 (cg-RX-API-DMAC7.html)
JP2018535650A5 (cg-RX-API-DMAC7.html)
JP2012121878A5 (cg-RX-API-DMAC7.html)
JP2017507652A5 (cg-RX-API-DMAC7.html)
JP2007510639A5 (cg-RX-API-DMAC7.html)
JP2017048208A5 (cg-RX-API-DMAC7.html)
JP2009511480A5 (cg-RX-API-DMAC7.html)
JP2015534578A5 (cg-RX-API-DMAC7.html)
JP2008538564A5 (cg-RX-API-DMAC7.html)
RU2016130056A (ru) Способы лечения кожной инфекции путем введения антагониста il-4r
JP2014525933A5 (cg-RX-API-DMAC7.html)
RU2016116949A (ru) Анти-лпс о11-антитело
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
JP2014524902A5 (cg-RX-API-DMAC7.html)
JP2017519768A5 (cg-RX-API-DMAC7.html)